… ProQR traite le premier patient dans l’essai STELLAR de Phase … CAMBRIDGE, Massachusetts, 11 mars 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société consacrée à … STELLAR examinera si le QR-421a (traitement par ARN de ProQR) peut ralentir la progression de la maladie, voire …
… ProQR Reaches Agreement with the FDA on Design of Phase 2/3 … & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development of ProQR. “Our regulatory discussions have been very …
… ProQR Announces Positive Findings From an Interim Analysis in … pandemic expected to impact timelines for the pipeline ProQR anticipates its cash runway will fund operations into … Executive Vice President of Research and Development of ProQR. “We are pleased with the current safety profile and …
… ProQR to Present at the Retinal Cell and Gene Therapy … & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Leber congenital amaurosis (LCA10) Presenter: Dr. Stephen R. Russell, Iowa University Presentation type: Oral …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … information or to RSVP, please contact Sariette Witte at ir@proqr.com . OTS The abstract titled: 'QR-010 penetrates …
… ProQR to present QR-010 data at the European Cystic Fibrosis … QR-010 can treat all manifestations of CF,” said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “I am very pleased that enrollment of the Phase 1b …
… ProQR Receives Orphan Drug Designation from FDA for Drug … Present Data at two Scientific Conferences Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis … David M. Rodman, MD, Chief Development Strategy Officer of ProQR, “It highlights the unmet need in this devastating …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … molecule that will move into clinical development using ProQR’s RNA approach. ARVO The p.Cys998X mutation which is a …
… ProQR to Present Interim Phase 1/2 Results for QR-110 in … and will be made available in the “Investors” section of ProQR’s website ( www.proqr.com ) under “Events and Presentations”. About …
… ProQR Announces Positive Interim Results from Phase 1/2 … & CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … executive vice president of research and development of ProQR. “We observed a clinically meaningful improvement in …